CDK Inhibitors: From the Bench to Clinical Trials

2010 ◽  
Vol 11 (3) ◽  
pp. 279-290 ◽  
Author(s):  
Flavio Rizzolio ◽  
Tiziano Tuccinardi ◽  
Isabella Caligiuri ◽  
Chiara Lucchetti ◽  
Antonio Giordano
2010 ◽  
Vol 999 (999) ◽  
pp. 1-12
Author(s):  
Flavio Rizzolio ◽  
Tiziano Tuccinardi ◽  
Isabella Caligiuri ◽  
Chiara Lucchetti ◽  
Antonio Giordano

Author(s):  
E. Panagiotou ◽  
G. Gomatou ◽  
I. P. Trontzas ◽  
N. Syrigos ◽  
E. Kotteas

2019 ◽  
Vol 18 (9) ◽  
pp. 1241-1251 ◽  
Author(s):  
Fengquan Chen ◽  
Chunxi Liu ◽  
Jian Zhang ◽  
Wenfang Xu ◽  
Yingjie Zhang

The Cyclin-Dependent Kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents. The CDK inhibitors can effectively suppress the excessive proliferation of tumor cells by inducing cell cycle arrest. In recent years, a large number of CDK inhibitors have entered pre-clinical and/or clinical trials. Among these compounds, the selective CDK4/6 inhibitor Palbociclib has been approved by FDA for breast cancer treatment. Moreover, Palbociclib demonstrated promising antitumor potential as monotherapy or combined therapy in numerous clinical trials. Herein, we provide a brief review focused on the recent progress of clinical studies about Palbociclib.


Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.


2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A410-A410
Author(s):  
T KOVASC ◽  
R ALTMAN ◽  
R JUTABHA ◽  
G OHNING

Sign in / Sign up

Export Citation Format

Share Document